Cysteamine delivery

Cysteamine delivery" refers to technologies and drug formulations designed to administer the small molecule cysteamine—most commonly for the treatment of nephropathic cystinosis or ocular cystinosis. Cysteamine acts by converting cystine to cysteine and mixed disulfides within lysosomes, reducing cystine buildup in affected tissues[1][4][5]. Drug delivery research in this context focuses on optimizing the absorption, biodistribution, and stability of cysteamine in formulations such as oral capsules/tablets (Cystagon, Procysbi) or topical ophthalmic gels and drops (Cystaran, Cystadrops)[3][5][6]. These delivery systems aim to improve patient adherence, ensure consistent drug exposure, and minimize dosing burden by providing sustained-release or enhanced tissue penetration, particularly in the eye[3][5]. Novel delivery platforms include hydrogels, nanowafers, and microsphere-based depots for improved ocular delivery[3][5]. However, as "cysteamine delivery" does not describe a molecular target, enzyme, receptor, or transporter, it should not be listed as a pharmacological target. It is correctly classified as a pharmaceutical research area concerning drug formulation and administration—not a molecular entity or target[1][3][5].

Other names

Cysteamine drug deliverycysteamine sustained-release deliveryocular cysteamine deliverycysteamine formulation